EMMA — Emmaus Life Sciences Share News
0.000.00%
Last trade - 00:00- $4.04m
- $30.07m
- $12.45m
Brief: Emmaus Life Sciences Reinforces Positive Outcomes Of Endari Clinical Trials, Including Efficacy Findings That Led To FDA Approval
Brief: Emmaus Life Sciences Announces Withdrawal Of Marketing Authorization Application To European Medicines Agency
U.S. STOCKS ON THE MOVE-Wendy's, Mallinckrodt, AVEO Pharma, Yield10, Francesca's, Emmaus, Sonim
Emmaus stock plunges on delisting from Nasdaq
Brief: Emmaus Life Sciences Granted European Patent For Use Of Pharmaceutical-Grade L-Glutamine In Treating Diverticulosis
Brief: Emmaus Life Sciences Announces Addition Of Oncology Supply As Distributor Of Endari
Brief: Telcon Rf Pharmaceuticals Inc Reports 8.7% Passive Stake In Emmaus Life Sciences Inc As Of July 17
Emmaus rises as blood disorder drug powers Q2 sales surge
Brief: Emmaus Life Sciences Says Net Revenues Of EMI For 2019 Q2 Increased 128% To $5.9 Mln
Brief: Emmaus Life Sciences Reiterates Financial Benefits From Recent Merger
Brief: Yutaka Niihara Reports 25.6% Stake In Emmaus Life Sciences Inc As Of July 17
Brief: Emmaus Life Sciences Details Financial Benefits From Recent Merger
NASDAQ RESUMED
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE
NASDAQ RESUMED
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE
Brief: Emmaus Life Sciences Receives Notice Of Nasdaq Delisting Following Merger With Mynd Analytics
NASDAQ RESUMED
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE